The development of mRNA vaccines represents one of the most significant scientific achievements of the past decade. From the rapid deployment of COVID-19 vaccines by Pfizer-BioNTech and Moderna to the expanding pipeline of mRNA therapeutics for oncology, rare diseases, and protein replacement therapies, the mRNA therapeutics field has demonstrated remarkable potential. However, as promising candidates move from early research through clinical development toward commercial manufacturing, the challenge of mRNA purification scale-up becomes increasingly critical.
Scaling up mRNA purification is not simply about running larger volumes through the same columns. The transition from micrograms to milligrams, from milligrams to grams, and ultimately from grams to kilograms requires fundamental changes in process design, equipment selection, quality control strategies, and regulatory compliance. This comprehensive guide walks through the complete journey of mRNA manufacturing purification, providing practical insights for researchers and process developers working to bring mRNA therapeutics from the laboratory bench to patients.
The success of mRNA vaccines against COVID-19 validated decades of foundational research and established a new paradigm for rapid vaccine development. Both the Pfizer-BioNTech Comirnaty vaccine and the Moderna Spikevax vaccine achieved emergency use authorization within less than a year of SARS-CoV-2 sequence publication—a feat previously thought impossible for traditional vaccine platforms.
These vaccines owe their success, in part, to advances in mRNA purification that enabled production at unprecedented scale while meeting stringent quality requirements. The ability to purify mRNA to greater than 95% purity with high integrity and consistent capping efficiency became the foundation for vaccine safety and efficacy.
Beyond COVID-19, the mRNA therapeutics pipeline has expanded dramatically. Clinical programs now target:
- Oncology: Personalized cancer vaccines encoding tumor-associated antigens, with Moderna and BioNTech reporting promising results in melanoma and other solid tumors
- Rare Diseases: Protein replacement therapies for conditions like methylmalonic acidemia (MMA) and propionic acidemia (PA)
- Infectious Diseases: Vaccines for influenza, RSV, CMV, and Zika virus
- Protein Expression: In vivo expression of therapeutic proteins including antibodies, enzymes, and cytokines
This pipeline growth translates directly into increased demand for scalable mRNA purification solutions. Process development teams must plan for scale-up early, as retrofitting processes designed at milligram scale for gram-scale production introduces significant delays and costs.
mRNA manufacturing purification faces unique challenges compared to traditional biologics:
- mRNA size and fragility: Full-length mRNA (typically 1-5 kb for therapeutic applications) is susceptible to shear stress, enzymatic degradation, and chemical modification during processing
- Impurity profile complexity: Process-related impurities (enzymes, nucleotides, DNA template) and product-related impurities (truncated species, double-stranded RNA, aggregates) require orthogonal purification strategies
- Capping efficiency consistency: The proportion of correctly capped mRNA affects translational efficiency and immunogenicity—variability at scale must be minimized
- Regulatory expectations: Regulatory agencies expect process consistency and validated manufacturing methods that ensure product quality across batches
A fundamental principle of mRNA purification scale-up is that processes do not always scale linearly. A method that works excellently at 1 mL may fail spectacularly at 1 L—and not always for obvious reasons.
Consider a simple example: at 1 mL scale, a 5-minute incubation step may seem instantaneous relative to overall process time. At 1,000 L scale, that same incubation represents an enormous hold tank requirement and extended residence time that may compromise mRNA integrity. Flow rates that produce minimal backpressure at laboratory scale create unmanageable pressures at process scale.
Similarly, mixing efficiency changes dramatically with scale. A pipette thoroughly mixes a 1 mL sample; a magnetic stir bar in a 1 L bioreactor creates different flow patterns than a 10,000 L tank's agitation system. These hydrodynamics affect binding kinetics, gradient formation, and cleaning validation.
When considering how to scale an Oligo dT affinity purification step, teams face a choice between multiple smaller columns operated in series and single larger columns. Each approach offers advantages:
Multiple Smaller Columns (Series Operation) :
- Lower capital investment per unit capacity
- Flexibility to add or remove columns based on load
- Easier to manage at early clinical scale
- Higher surface-area-to-volume ratio can improve binding kinetics
Single Larger Column:
- Simpler validation and documentation
- Reduced product hold time between operations
- Consistent flow distribution and residence time
- Lower column-to-column variability
For most early-phase clinical programs, starting with prepacked 1 mL columns and transitioning to 5 mL columns or bulk resin packed into process columns represents the most practical approach. This staged progression minimizes risk while building process knowledge.
Understanding mRNA manufacturing purification costs at different scales is essential for project planning and investor communications:
| Scale |
Typical Application |
Cost Drivers |
| μg to mg |
Research, early discovery |
Column cost dominates |
| mg to g |
Pilot studies, IND-enabling |
Column cost + buffer + labor |
| g to kg |
Clinical manufacturing |
Facility overhead + consumables |
AHELIXBIOTECH Oligo dT25 columns provide a clear cost advantage at every scale. The SA099C11 1 mL column at $199 enables cost-effective method development, while bulk resin pricing delivers significant savings at manufacturing scale. Compared to competing products like Thermo Scientific POROS Oligo(dT)25 (1 mL at $417), AHELIXBIOTECH columns reduce consumable costs by over 50%—a meaningful advantage when running hundreds of batches annually.
At laboratory scale, the primary goal is method development—establishing optimal conditions for binding, washing, and elution while characterizing the impurity profile. 1 mL Oligo dT columns like the AHELIXBIOTECH SA099C11 provide the ideal platform for this work.
The SA099C11 column uses the same Oligo dT25 ligand chemistry that scales to manufacturing, ensuring that conditions optimized at bench scale transfer directly to process scale. This ligand consistency eliminates the re-optimization often required when switching between different resin chemistries during scale-up.
When selecting mRNA batches for purification method development, consider:
- Diversity of impurity profile: Include batches with varying levels of dsRNA, truncated transcripts, andcapping efficiency (capping efficiency)
- Expression system consistency: Use mRNA produced with the same IVT platform planned for clinical manufacturing
- Template quality: Assess DNA template purity and integrity before initiating IVT reactions
- Scale-appropriate volumes: Generate sufficient crude mRNA for multiple purification runs with reserve for method optimization
Key parameters to optimize during laboratory-scale mRNA purification:
Binding Conditions:
- Buffer composition (typically high-salt loading to promote poly-A tail binding)
- Flow rate (slower flow rates improve binding capacity but extend process time)
- Load ratio (mRNA per mL of resin—typically 0.5-2 mg/mL for optimal purity)
- Temperature (ambient temperature is standard; refrigerated operation may benefit unstable mRNA)
Wash Conditions:
- Wash volume (3-5 column volumes typically sufficient)
- Wash buffer stringency (salt concentration gradient to remove loosely bound impurities)
- Optional detergent wash (for removal of hydrophobic impurities or residual lipids)
Elution Conditions:
- Elution buffer composition (low-salt or water with gentle pH adjustment)
- Elution volume (minimize dilution for downstream concentration steps)
- Pooling strategy (UV monitoring for peak collection)
Transitioning from 1 mL method development to pilot-scale production requires columns that balance throughput with practical handling. The AHELIXBIOTECH 5 mL Oligo dT25 columns (SA099C51) provide this capability, offering:
- 5× the capacity of 1 mL columns in a single unit
- Identical ligand chemistry for seamless scale-up
- Compatibility with standard chromatography systems
- Validated performance specifications
At pilot scale, the shift from manual operation to automated chromatography systems becomes important. Standard FPLC or ÄKTA systems can operate 5 mL columns with appropriate gradient capabilities, backpressure monitoring, and fraction collection.
Throughput Optimization:
At pilot scale, process economics matter more than at laboratory scale. Consider:
- Cycle time reduction: Parallel processing steps (equilibration during elution concentration) can reduce overall processing time
- Load optimization: Maximize loading per cycle while maintaining purity specifications
- Buffer scaling: Prepare buffers in volumes appropriate for multiple cycles; single batches should support at least 10 cycles
Buffer Preparation at Scale:
Scaling buffer preparation requires attention to:
- Dissolution time: Larger volumes of high-salt buffers require longer dissolution and mixing times
- Filtration: All buffers must be filtered (0.22 μm or 0.45 μm) before use; larger vessels require larger filter assemblies or in-line filtration
- Quality control: Implement buffer identity, pH, and conductivity testing before releasing for production use
- Storage stability: Confirm buffer storage conditions and expiry dates at scale
Column Lifetime:
Prepacked columns offer defined lifetime specifications. At pilot scale, track:
- Binding capacity over cycles
- Backpressure trends
- Purity and yield consistency
- Column integrity test results
This data supports regulatory submissions and informs column procurement planning for clinical manufacturing.
For clinical and commercial mRNA manufacturing purification, bulk resin procurement provides the most cost-effective approach. AHELIXBIOTECH offers Oligo dT25 bulk resin for process-scale applications, enabling:
- Custom column packing to exact dimensions required for your facility
- Consolidated supply agreements with volume-based pricing
- Technical support for column packing and validation
- Supply chain security through redundant manufacturing
When evaluating bulk resin, request:
- Batch-specific Certificate of Analysis with binding capacity, selectivity, and physical properties
- Regulatory support documentation (Drug Master File availability, animal-origin statements)
- Sample lots for internal qualification studies
Process-scale chromatography requires specialized equipment:
ÄKTA Process Systems:
- Designed for industrial-scale purification
- Flow rates from hundreds to thousands of mL per minute
- Sanitary design with validated cleaning
- Integrated control systems for regulatory compliance
Custom Skids:
- Purpose-built for specific product applications
- Often required for very large-scale operations
- Higher capital cost but optimized for specific processes
- Can incorporate in-line dilution, buffer blending, and continuous processing capabilities
Critical Considerations:
- Flow distribution: Large-diameter columns require careful flow distributor design to prevent channeling
- Backpressure management: Process systems must deliver consistent pressure across the column
- Cleaning validation: Systems must enable validated cleaning between batches
- Single-use options: For multi-product facilities, single-use flow paths reduce changeover time and cross-contamination risk
Manufacturing mRNA vaccine development products for clinical trials requires compliance with current Good Manufacturing Practice (cGMP) regulations. Key considerations include:
Drug Master File (DMF) :
- A DMF filed with regulatory agencies contains confidential manufacturing information
- AHELIXBIOTECH provides comprehensive DMF support for Oligo dT25 resin
- DMF cross-reference in your IND/BLA streamlines regulatory review
Validated Processes:
- Process validation studies demonstrate that the purification process consistently produces product meeting specifications
- Validation protocols must address installation qualification (IQ), operational qualification (OQ), and performance qualification (PQ)
-worst-case challenge studies confirm process robustness
GMP Compliance:
- GMP facilities require qualified equipment, trained personnel, and validated procedures
- Batch records must capture all critical process parameters
- Change control procedures govern any process modifications
Quality by Design (QbD) principles, as described in ICH Q8-Q12 guidelines, provide a systematic framework for mRNA manufacturing purification process development. The approach begins with defining Critical Quality Attributes (CQAs)—product characteristics that must be controlled to ensure safety and efficacy.
For purified mRNA, typical CQAs include:
| CQA |
Target |
Analytical Method |
| Purity (full-length) |
≥95% by CE/CGE |
Capillary electrophoresis |
| Integrity (Fragmentation) |
≥85% intact |
Agarose gel, CE |
| Capping efficiency |
≥90% Cap 1 |
LC-MS, ELISA |
| Poly(A) tail distribution |
Consistent with reference |
Extension assay |
| Residual dsRNA |
<0.1% |
ELISA (J2 antibody) |
| Endotoxin |
<10 EU/mL (final dose) |
LAL assay |
| Sterility |
No growth |
USP <71> |
Critical Process Parameters (CPPs) are input variables that affect CQAs. For Oligo dT affinity purification, relevant CPPs include:
mRNA Load:
- Amount of mRNA loaded per mL of resin
- Target: 0.5-2 mg/mL depending on purity requirements
- Impact: Overloading reduces purity; underloading reduces productivity
Flow Rate:
- Expressed as residence time (volume/flow rate)
- Target: 1-3 minute residence time for binding
- Impact: Too fast reduces binding capacity; too slow extends process time
Buffer pH:
- Optimal binding at pH 7.0-7.5
- Impact: Deviation affects charge interactions and mRNA stability
Conductivity:
- High salt concentration (0.5-1.0 M) for binding
- Impact: Conductivity outside range affects binding selectivity
The Design Space defines the proven acceptable ranges (PARs) for each CPP within which quality is assured. Operating within the Design Space is not considered a process change; operating outside requires regulatory notification.
For mRNA purification scale-up, the Design Space typically encompasses:
- Load ratio: 0.5-3.0 mg/mL
- Residence time: 0.5-5 minutes
- pH: 6.8-7.8
- Conductivity: 0.3-1.2 M NaCl equivalent
Process characterization studies (often using Design of Experiments, DOE) establish these ranges experimentally, demonstrating that the process remains robust across the anticipated operating space.
Regulatory submissions for mRNA therapeutics require comprehensive process validation data. The validation program typically includes:
Stage 1: Process Design:
- Define manufacturing process through development studies
- Establish control strategy based on risk assessment
- Identify scale-up considerations
Stage 2: Process Qualification:
- Prospective validation runs at commercial scale (or representative scale)
- Demonstrate reproducibility across multiple batches
- Confirm Design Space boundaries
Stage 3: Continued Process Verification:
- Ongoing monitoring of process performance
- Trend analysis of CQAs and CPPs
- Periodic review and updating of control strategy
All raw materials used in mRNA purification must be qualified:
- Supplier qualification: Audit of critical suppliers including resin manufacturers
- Incoming quality control: Testing of each lot against specifications
- Certificate of Analysis review: Verification that released materials meet requirements
- Supply continuity: Agreements for backup suppliers or safety stock
For Oligo dT25 resin, qualification packages should include:
- Binding capacity specification and test method
- Selectivity data for mRNA vs impurities
- Compatibility with cleaning and storage conditions
- Regulatory support file cross-reference
Complete batch records capture:
- All raw material lot numbers and expiry dates
- Equipment identification and calibration status
- Critical and non-critical process parameters
- In-process control results
- Deviation reports (if any)
Change control procedures ensure that modifications to equipment, materials, or processes are evaluated for impact on product quality and regulatory status. Even minor changes (e.g., resin lot change) may require re-qualification studies.
Successful mRNA purification scale-up requires thoughtful planning from the earliest stages of research. Key principles for navigating the journey from laboratory to manufacturing:
Not all purification methods are created equal in their scalability potential:
- Oligo dT affinity chromatography: Highly scalable; the same ligand chemistry applies from 1 mL to 1,000 L
- LiCl precipitation: Works at small scale but presents significant challenges for manufacturing (filterability, residual salts, reproducibility)
- Ion exchange chromatography: Scalable but requires more process development to achieve equivalent selectivity to affinity methods
By beginning with Oligo dT affinity purification, you establish a foundation that scales directly to clinical manufacturing. The time invested in optimizing conditions at 1 mL pays dividends when those same conditions transfer to pilot and production scales.
Good documentation practices are not optional—they are the foundation of regulatory compliance and process improvement:
- Record all experimental conditions, even for failed experiments
- Use standardized templates for batch records and development reports
- Maintain clear chain of custody for samples
- Archive data in compliant electronic systems
Documentation created during early research becomes the historical basis for process validation at manufacturing scale.
Your chromatography resin supplier becomes a critical partner in mRNA vaccine development:
- Engage early to understand regulatory support capabilities (DMF availability, characterization data)
- Establish communication channels for technical troubleshooting
- Negotiate supply agreements that ensure continuity of supply
- Request pilot-scale samples for qualification before committing to clinical supply
AHELIXBIOTECH offers comprehensive support for mRNA purification scale-up, from the SA099C11 1 mL development column at $199 to bulk resin for manufacturing-scale operations. Our Oligo dT25 ligand chemistry is consistent across all formats, enabling seamless process transfer.
From 1 mL method development to process-scale purification, our Oligo dT25 columns and bulk resin provide a seamless scale-up path. Start with 1 mL prepacked columns at $199, then move to bulk resin as your project grows.
Ready to scale your mRNA purification process?
This article is intended for research use only (RUO). For GMP manufacturing applications, please inquire about our clinical-grade product offerings.
